Clinical characteristics (n = 50).
| Characteristics | n (%) or Mean ± SD |
|---|---|
| Age, yrs | 31 ± 5.2 |
| Body mass index, kg/m2 | 28.2 ± 5.6 |
| Diagnosis | |
| SLE | 28 (56) |
| RA or JIA | 7 (14) |
| Undifferentiated CTD | 5 (10) |
| Other* | 10 (20) |
| Race | |
| White | 32 (64) |
| Black/African American | 16 (32) |
| Other | 2 (4) |
| Corticosteroids | |
| Use, concomitant | 14 (28) |
| Average dose, mg | 16.7 ± 11 |
| Maximum dose, mg | 21.3 ± 19 |
| AZA use, concomitant | 9 (18) |
| Disease activity | |
| SLE PGA (0–3 cm) | 0.5 ± 0.6 |
| Non-SLE PGA (0–100 mm) | 11.9 ± 12.7 |
Categorical variables listed as n (%); continuous variables listed as mean ± SD.
↵* Other diagnoses included antiphospholipid antibody syndrome (n = 1), autoimmune hepatitis (n = 1), cutaneous SLE (n = 2), psoriatic arthritis (n = 1), SSc (n = 1), Sjögren syndrome (n = 3), and positive ANA/Ro (n = 1). SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; JIA: juvenile idiopathic arthritis; CTD: connective tissue disease; AZA: azathioprine; PGA: physician’s global assessment; ANA: antinuclear antibody; SSc: systemic sclerosis.